BNR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BN

Mkt Cap

$136.6M

Volume

24.50K

Next Earnings

November 19th

Loading chart

BN

BNRBurning Rock Biotech Limited American Depositary Shares

BNR

Pay with—

Available Balance0.00

BN

Mkt Cap

$164.5M

Volume

24.50K

Next Earnings

November 19th

Chart Financials Earnings News About Insider Filings

Cancer screening company Faces Tough IPO Test As Market CoolsWuhan Ammunition Life-tech Co. Ltd., a Chinese cancer screening company, is making a second attempt to list on the Hong Kong Stock Exchange amid a cooling biotech market. Despite doubling revenues to 15.42 million yuan in 2025, the company's net losses widened 26.8% and it faces a challenging valuation of 147x price-to-sales ratio. The sector has faced significant headwinds, with peers like New Horizon Health suspended for misconduct and Burning Rock Biotech facing delisting warnings.Benzinga · Apr 16, 2026

Burning Rock Announces Results of 2025 Annual General MeetingBurning Rock Biotech Limited (NASDAQ: BNR) announced that all shareholder resolutions at its 2025 annual general meeting held on December 22, 2025 were approved. The resolutions included ratifying Ernst & Young Hua Ming LLP as auditor, re-electing directors Feng Deng and Licen Lisa Xu, and authorizing directors to implement the resolutions.GlobeNewswire Inc. · Dec 23, 2025

Burning Rock Reports Third Quarter 2025 Financial ResultsBurning Rock Biotech reported Q3 2025 financial results with total revenues of RMB 131.6 million, a slight 2.3% increase from the same period in 2024. The company saw decreased revenues in in-hospital and central laboratory channels but significant growth in pharma research and development services. Net loss was RMB 16.8 million, an improvement from RMB 35.7 million in the previous year.GlobeNewswire Inc. · Nov 20, 2025

Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast CancerBurning Rock and Riken Genesis received approval in Japan for a companion diagnostic system to guide treatment decisions for hormone-receptor-positive breast cancer patients using capivasertib.GlobeNewswire Inc. · Sep 24, 2025

Burning Rock Reports Second Quarter 2025 Financial ResultsBurning Rock Biotech reported Q2 2025 revenues of RMB148.5 million, a 9.6% increase from the same period in 2024. The company reduced operating expenses by 42.1% through budget control and improved efficiency, resulting in a narrowed net loss of RMB9.7 million compared to RMB108.0 million in the previous year.GlobeNewswire Inc. · Sep 8, 2025

Companion Diagnostic Markets Report 2025-2029: Diagnostic Firms Jockey for Position as Pharmaceutical Partnerships Flourish, Discover the Impact of AIThe report examines the rapidly evolving companion diagnostics market, driven by advancements in artificial intelligence and the formation of innovative partnerships between diagnostic and pharmaceutical companies. It provides insights into market trends, growth opportunities, and the impact of emerging technologies across 18 countries and 4 regions.GlobeNewswire Inc. · Jun 6, 2025

Burning Rock Reports First Quarter 2025 Financial ResultsBurning Rock Biotech Limited reported its financial results for the first quarter of 2025, with revenue growth and improved profitability. The company's therapy selection and minimal residual disease (MRD) products showed promising results in clinical studies.GlobeNewswire Inc. · Jun 6, 2025

Burning Rock Announces Results of 2024 Annual General MeetingBurning Rock Biotech Limited (BNR) announced that all shareholder resolutions proposed at its 2024 annual general meeting were passed, including the re-election of directors and the appointment of Ernst & Young Hua Ming LLP as the company's auditor.GlobeNewswire Inc. · Dec 31, 2024

Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024Burning Rock Biotech Limited, a company focused on precision oncology, announced that it will hold its annual general meeting on December 31, 2024. The meeting will include proposals to ratify the appointment of Ernst & Young as the company's auditor and to re-elect two directors.GlobeNewswire Inc. · Dec 3, 2024

NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in ChinaBurning Rock Biotech and Dizal announced that the companion diagnostic (CDx) for EGFR exon 20 insertion mutation for sunvozertinib has been approved by the NMPA of China, marking the first co-developed NGS-based CDx for lung cancer approved in the country.GlobeNewswire Inc. · Oct 11, 2024

to start trading

BN

BNRBurning Rock Biotech Limited American Depositary Shares

BNR

Pay with—

Available Balance0.00

Your PositionYou don't own any BNR yet.

Related Tickers

Earnings